Open AccessXanthine oxidase inhibition in SARS-CoV-2 infection: the mechanism and potency of allopurinol and febuxostat in COVID-19 management
Author(s) -
Irandi Putra Pratomo,
Anna Ariane,
Aryo Tedjo,
Rudi Heryanto,
Rafika Indah Paramita
Publication year - 2020
Publication title -
medical journal of indonesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.164
H-Index - 9
eISSN - 2252-8083
pISSN - 0853-1773
DOI - 10.13181/mji.rev.204641
Subject(s) - febuxostat , allopurinol , covid-19 , xanthine oxidase , medicine , uric acid , xanthine oxidase inhibitor , hyperuricemia , pharmacology , gout , coronavirus , mechanism (biology) , virology , disease , biology , enzyme , infectious disease (medical specialty) , biochemistry , philosophy , epistemology , outbreak
The number of coronavirus disease 2019 (COVID-19) infection cases has been increasing globally, including in Indonesia Definitive therapy for COVID-19 has not yet been found;hence, repurposed drugs for COVID-19 have been considered and have been practiced by several researchers in the world This literature review investigates the action of xanthine oxidase as a component of the biomolecular pathway against severe acute respiratory syndrome-related coronavirus-2, the cause of COVID-19, and describes the mechanism and potential of uric acid drugs (allopurinol and febuxostat) as prophylaxis and curative therapy for COVID-19
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom